Veracyte, Inc.
VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$44.61
Price-5.91%
-$2.80
1Y
Price
Market Cap
$3.526b
Mid
Price/Earnings 3y Avg5y Avg
117.4x
Premium
Premium
Financials Overview
Key metrics over the past few years+18.3%
EBITDA Margin+14.5%
Net Profit Margin+31.8%
Free Cash Flow MarginRevenue
$495.141m
+11.1%
1y CAGR+18.8%
3y CAGR+22.9%
5y CAGREarnings
$30.317m
+25.6%
1y CAGR+18.2%
3y CAGR+26.5%
5y CAGREPS
$0.38
+22.6%
1y CAGR+17.7%
3y CAGR+26.8%
5y CAGRBook Value
$1.258b
$1.368b
Assets$110.120m
Liabilities$40.453m
DebtDebt to Assets
3.0%
0.9x
Debt to EBITDAFree Cash Flow
$98.210m
+53.9%
1y CAGR+1206.3%
3y CAGR+929.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company